Team Blitz India
NEW DELHI: The Department of Biotechnology (DBT) announced on June 20, that it had developed a Omicron-specific mRNA-based Booster vaccine using the indigenous platform technology.
The vaccine developed by Gennova Biopharmaceuticals Ltd. and supported under the Mission COVID Suraksha, has got the nod from the office of the Drug Control General of India (DCGI) for Emergency Use Authorization (EUA).
DBT has facilitated establishing Gennova’s mRNA-based next-generation vaccine manufacturing for developingthe platform technology from proof of concept till Phase I clinical trial of the prototype mRNA-based vaccine developed against the Wuhan strain.
The project was further aided and supported under the ‘Mission COVID Suraksha.
